The plain answer in this month's tirzepatide news is that Mounjaro now has a heart-risk indication for certain adults with type 2 diabetes. That change does not apply to Zepbound or to compounded tirzepatide. Other developments this quarter affected labeling, Medicare access, compounding rules, online peptide sellers, and research.
As of September 9, 2026, the day this article was written, the Mounjaro label change was the development most likely to affect a medical conversation right away.
Changelog
September 1 — FDA posted five online-seller warning letters. The letters were dated August 24 and named products marketed as tirzepatide among other peptides. FDA said the websites' claims and sales setup showed that the products were being offered as unapproved drugs. A warning letter is an agency notice, not a court ruling. The FDA index lists all five letters, and the full warning-letter breakdown explains what they do and don't mean.
August 31 — Lilly released one-year TOGETHER data. The company reported that adding Zepbound to Taltz was associated with maintained or further improvement through week 52 in two studies of adults with psoriatic disease and obesity or qualifying overweight. The trials enrolled 274 people with psoriasis and 271 with psoriatic arthritis. These were company-reported exploratory findings, meaning they were not the main test the trials were designed around, and detailed results were not yet peer reviewed.
August 28 — Mounjaro's cardiovascular wording became public. FDA's supplement letter, signed August 27, added a use: lowering the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in adults with type 2 diabetes who are at high risk. The supporting SURPASS-CVOT trial randomized 13,299 people. Tirzepatide was noninferior to dulaglutide—meaning it met the study's standard for not being meaningfully worse—but superiority was not established (Nicholls et al., New England Journal of Medicine, 2025).
August 28 — the Zepbound label was refreshed. DailyMed says the prescribing information was updated August 28 and revised 8/2026. The recent-change table added diabetic-retinopathy monitoring for patients with type 2 diabetes and a history of that eye disease. Zepbound's listed uses remained long-term weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
August 27 — the Fifth Circuit upheld FDA's shortage decision. The court affirmed the judgment for FDA in the tirzepatide case. It rejected the effort to overturn the agency's decision that the national shortage had ended. The opinion did not erase the separate, narrower rules for prescriptions prepared for an identified patient; the shortage court ruling owns that distinction in detail.
July 21 — Novo Nordisk sued Lilly over comparative ads. Novo said Lilly's Zepbound and Mounjaro ads relied on comparisons that did not include newer, higher-dose semaglutide data. That is an allegation, not a court finding, and separate trials cannot create a new head-to-head result. Novo's announcement confirms the filing date and claims; the lawsuit explainer keeps the advertising dispute separate from a treatment decision.
July 1 — Medicare's GLP-1 Bridge began. Eligible Medicare Part D beneficiaries can receive certain weight-management medicines for a $50 monthly copay after prior authorization. For tirzepatide, CMS lists only Zepbound KwikPen, a four-dose pen for one patient. Single-dose Zepbound pens and vials are not included in the Bridge.
June 26 — FDA extended comments on its 503B proposal. Section 503B covers outsourcing facilities, compounding operations that can prepare office stock under added federal requirements. The Federal Register notice extended comments through July 30 on FDA's proposal not to add tirzepatide, semaglutide, or liraglutide to the 503B bulks list. No final notice had appeared by September 9, so the April 30 action remained a proposal.
September 9 status — FDA's compounded-product report count still used May 31 data. FDA listed more than 730 adverse-event reports associated with compounded tirzepatide. An adverse-event report records something unwanted after treatment; it does not prove the product caused it. FDA also says these reports are likely incomplete because many state-licensed pharmacies are not required to submit them.
What the tirzepatide news means now
Tirzepatide is a dual GIP and GLP-1 receptor agonist, a medicine that acts on two hormone pathways involved in blood sugar and appetite. Mounjaro and Zepbound contain the same molecule but remain different branded products with different labeled uses. The August heart update belongs to Mounjaro and to the specific high-risk diabetes population named in its label.
The standing weight evidence did not change this quarter. In SURMOUNT-1, a 2022 trial of 2,539 adults without diabetes, average weight change at 72 weeks was −15.0%, −19.5%, and −20.9% across the three tirzepatide groups, compared with −3.1% on placebo (Jastreboff et al., New England Journal of Medicine, 2022). Those are trial averages, not a forecast for one person or proof about every formulation.
Semaglutide remains a separate molecule and a separate prescribing choice. The July advertising case did not settle which option is better for an individual, and the Medicare Bridge includes eligible presentations of both medicines.
What did not change for compounded tirzepatide
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The Mounjaro label update does not transfer its cardiovascular indication to a pharmacy-prepared formulation, and branded-trial results do not establish that every compounded preparation is equivalent.
The August warning letters also did not announce a new rule for all peptide care. They describe what FDA said five sellers did. The useful contrast is the route: a prescribed medication has a named reviewing clinician, an identified licensed U.S. pharmacy, a traceable lot and label, and a path for reporting a problem. A grey-market vial sold without clinical review does not provide that chain of accountability.
Regulatory status is one part of a clinical decision, not a marketing gate. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor.
What a provider considers in September 2026
The new heart wording matters only after the provider confirms which product, diagnosis, and risk profile are actually in front of them. The same review still covers thyroid-cancer history, pancreatitis or gallbladder history, kidney problems, diabetes medicines that can lower glucose, pregnancy, severe stomach symptoms, eye disease in someone with type 2 diabetes, and any planned procedure involving anesthesia. The prescriber sets the dose and pace from the person's history and tolerance.
At Promise, a licensed provider reviews every request and may prescribe or decline on medical eligibility; not everyone qualifies. If a compounded option is considered, how compounded tirzepatide works under the current rules explains the patient-specific route.
What to watch next
Four things could change the next quarterly update: publication of the full 52-week TOGETHER results, a court order or settlement in the advertising case, a final FDA decision on the 503B bulks proposal, and any newer FDA adverse-event count. The clean way to read each is to ask which exact product and patient group it covers. A headline about the molecule does not automatically rewrite every label or every prescription.